All News

exercise.workout.jpg

Young Males and Future Risk of MSK and Chronic Diseases

Jack Cush, MD

A large cohort of 18-year-old Swedish males were followed longitudinally for cardiovascular, respiratory, and musculoskeletal outcomes.

Read Article
celebrex.jpg

Celecoxib Lowers Colon Cancer Recurrence Risk

Jack Cush, MD

The Alliance for Clinical Trials in Oncology today announced the results of a data analysis from a randomized phase III clinical trial involving patients with stage III colon cancer, which found that adding the drug celecoxib

Read Article
Lifestyle diet alcohol risk obesity

Proinflammatory Diet Increases Gout Risk

MedPage Today

Some dietary habits are worse than others when it comes to gout risk for women, a large study indicated.

Read Article
uveitis eye iritis

Adalimumab Withdrawal in Uveitis Patients

Jack Cush, MD

Adalimumab is an effective treatment for JIA-associated uveitis and has been FDA approved for such use - but for how long and can the drug be withdrawn? An adalimumab (ADA) withdrawal trial has shown recurrence of uveitis, arthritis, or both, when the disease was previously controlled on ADA.

Read Article
Gout pills injection

Do Rheumatologists Follow 2020 ACR Guidelines on Gout?

Jack Cush, MD

Schlessinger and colleagues report that US Rheumatologists generally adhere to and agree with the 2020 American College of Rheumatology (ACR) Guideline for the Management of Gout, although knowledge gaps and practice variance exists.

Read Article
RheumNow Podcast square

Fallen Angels (1.17.2025)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com; and pays homage to colleagues who passed away in 2024.

Read Article
PMR,flag

BACHELOR Trial - Baricitinib in Early Polymyalgia Rheumatica

Jack Cush, MD

Lancet reports a French study demonstrating the efficacy of baricitinib in patients with polymyalgia rheumatica (PMR).

Read Article
Open label trial of starting MTX in 11 uncontrolled gout pts previously Rx w/ IV pegloticase (PEG 2-27x) showed if gout pts failed PEG monotherapy, only 1/11 (9%) showed a good response to adding MTX w/ PEG. MTX must be started w/ PEG initiation to work https://t.co/aoBtyIRbQe https://t.co/RNe03O6Z1N

Links:

Dr. John Cush RheumNow ( View Tweet)
Febuxostat (ULORIC) is discontinued by the manufacturer in the USA. This week an FDA update on drug shortages list announced Uloric has been discontinued. Takeda sited dropping sales, generic competition, and CV safety concerns in the last decade. GENERIC febuxostat should still… https://t.co/QcUNCUFfvJ https://t.co/oBdwkcN177
Dr. John Cush RheumNow ( View Tweet)
post hoc analysis of 4 registration trials of pegloticase, show rates of MACE and Thromboembolic Events were Infrequent (<1.5%; 35.4 events/1000 PY), similar to general gout population (31.7 events/1000 person-years) https://t.co/v6ZqtL4yB2 https://t.co/NA0j20Oew2

Links:

Dr. John Cush RheumNow ( View Tweet)
Systematic review of 14 studies using administrative/med. records data on >130 million people & 1 million dementia cases, finds the risk of Alzheimers/Dementia reduced w/ Antimicrobials, vaccines & NSAID antiinflammatories (but incr w/ DM drugs, vitamins, antipsychotics)… https://t.co/p79s5Pw4k2 https://t.co/9DO1WO2NuG
Dr. John Cush RheumNow ( View Tweet)
ACR: Congress Fails to Reform PBMs, Mitigate Medicare Cuts Save The ACR praised the limited extension of Medicare telehealth coverage but criticized Congress for not passing measures to increase transparency in PBM practices, address insurer issues, or prevent upcoming Medicare… https://t.co/pJ5f6LvELe https://t.co/jT3UJAx5It
Dr. John Cush RheumNow ( View Tweet)
Medicare has announced another 15 expensive drugs (now total 25) undergoing price negotiation with manufacturers. Enbrel and Stelara were in the 1st ten. Included in the next 15 Rx are Ofev (nintenib) & Otezla (apremilast) & GLP-1 drugs. https://t.co/SBwSprvo6K… https://t.co/okJXJCgOFm https://t.co/im2ggtgvt3

Links:

Dr. John Cush RheumNow ( View Tweet)
FDA has sent a Drug Safety Letter to VETERINARIANS about the use of Librela (bedinvetmab) & reported adverse reactions, deaths and neurological problems (ataxia, seizures, paresis). Rx was approved 5/23 to treat pain from osteoarthritis in dogs. https://t.co/LIZ4ZzXtmk https://t.co/uOVc2xsD5g

Links:

Dr. John Cush RheumNow ( View Tweet)
Study of predominantly older males from the Veterans Health Administration (VHA) data, shows the use of b/ts-DMARDs is not associated with a risk for multiple myeloma. From 27,540 RA pts, 30% took b/tsDMARD, 77 incident MM (HR1.32;95% CI 0.78, 2.26) https://t.co/KZLEfq8vRK https://t.co/7qLQISRCoC

Links:

Dr. John Cush RheumNow ( View Tweet)
U.S. overdose deaths far outpace other countries. In 2023 US drug overdoses >100,000 for 3rd year — a >50% jump since 2019. 2022 rate=324/1 million. High rates attributed to fentanyl, polysubstance use, counterfeit pills, variance in state policies on harm reduction… https://t.co/IYpytkEgpt https://t.co/HrrU9SCJT1
Dr. John Cush RheumNow ( View Tweet)
BACHELOR Trial - Baricitinib in Early Polymyalgia Rheumatica Lancet reports a French study demonstrating the efficacy of baricitinib in patients with polymyalgia rheumatica (PMR). Glucocorticoids are the mainstay of therapy in PMR patients and may be problematic in older… https://t.co/svLmE6OBWm https://t.co/K8sdROswxV
Dr. John Cush RheumNow ( View Tweet)
Eltrombopag, a Potential New Treatment for ITP A pilot trial has shown a thrombopoietin receptor agonist, eltrombopag (Promacta), to be effective in connective tissue disease-related (CTD), refractory immune thrombocytopenia (ITP). https://t.co/hYSAEKOjq5 https://t.co/QzBNA3SWVo

Links:

Dr. John Cush RheumNow ( View Tweet)
SetPoint Medical has applied to FDA for pre-market approval of Vagal nerve neuroimmune modulation device to Rx mod-severe #RA, not responding to 2 biologics. Based on RESET-RA 242 pt, 12 wk RCT showing ACR20=35% vs 24% PBO resp. SAE only 1.7%. https://t.co/d8RfXBFUSS https://t.co/Fq1qkfo1NM

Links:

Dr. John Cush RheumNow ( View Tweet)
VA (Veterans) study of 531 RA-ILD (among 9,701 incident RA) vs 68,852 matched controls - finds exposure to fire smoke PM2.5 assoc w/ RA-ILD/aOR 1.98 (but not RA). NOx, ozone, and PM10 assoc w/ seroneg. RA risk (aOR 1.16-1.25) . Pollution increases risk of RA & RA-ILD… https://t.co/AuG4rRtx4r https://t.co/XyHtjrSfhi
Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×